Case report reveals rituximab improves bullous pemphigoid after nivolumab therapy, indicating treatment potential.
Drug-associated bullous pemphigoid (DABP) refers to cases of bullous pemphigoid caused by exposure to various drugs. We present a case of nivolumab (a programmed cell death-ligand 1 (PD-L1) inhibitor) induced bullous pemphigoid in a patient treated for classic Hodgkin’s lymphoma, presenting four months after cessation of therapy. The patient demonstrated minimal clinical response to steroids and methotrexate. Following initiation of rituximab, the patient experienced rapid improvement of the rash with no further disease progression
No takes yet. Share an insight, caveat, or question.
Amin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: